» Articles » PMID: 27378872

Dopamine Replacement Therapy, Learning and Reward Prediction in Parkinson's Disease: Implications for Rehabilitation

Overview
Specialty Psychology
Date 2016 Jul 6
PMID 27378872
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The principal feature of Parkinson's disease (PD) is the impaired ability to acquire and express habitual-automatic actions due to the loss of dopamine in the dorsolateral striatum, the region of the basal ganglia associated with the control of habitual behavior. Dopamine replacement therapy (DRT) compensates for the lack of dopamine, representing the standard treatment for different motor symptoms of PD (such as rigidity, bradykinesia and resting tremor). On the other hand, rehabilitation treatments, exploiting the use of cognitive strategies, feedbacks and external cues, permit to "learn to bypass" the defective basal ganglia (using the dorsolateral area of the prefrontal cortex) allowing the patients to perform correct movements under executive-volitional control. Therefore, DRT and rehabilitation seem to be two complementary and synergistic approaches. Learning and reward are central in rehabilitation: both of these mechanisms are the basis for the success of any rehabilitative treatment. Anyway, it is known that "learning resources" and reward could be negatively influenced from dopaminergic drugs. Furthermore, DRT causes different well-known complications: among these, dyskinesias, motor fluctuations, and dopamine dysregulation syndrome (DDS) are intimately linked with the alteration in the learning and reward mechanisms and could impact seriously on the rehabilitative outcomes. These considerations highlight the need for careful titration of DRT to produce the desired improvement in motor symptoms while minimizing the associated detrimental effects. This is important in order to maximize the motor re-learning based on repetition, reward and practice during rehabilitation. In this scenario, we review the knowledge concerning the interactions between DRT, learning and reward, examine the most impactful DRT side effects and provide suggestions for optimizing rehabilitation in PD.

Citing Articles

Goal-directed learning is multidimensional and accompanied by diverse and widespread changes in neocortical signaling.

Marrero K, Aruljothi K, Delgadillo C, Kabbara S, Swatch L, Zagha E Cereb Cortex. 2024; 34(8.

PMID: 39110412 PMC: 11304966. DOI: 10.1093/cercor/bhae328.


Normalization effect of dopamine replacement therapy on brain functional connectome in Parkinson's disease.

Wu C, Wu H, Zhou C, Guan X, Guo T, Cao Z Hum Brain Mapp. 2023; 44(9):3845-3858.

PMID: 37126590 PMC: 10203796. DOI: 10.1002/hbm.26316.


Encapsulation of MSCs and GDNF in an Injectable Nanoreinforced Supramolecular Hydrogel for Brain Tissue Engineering.

Torres-Ortega P, Del Campo-Montoya R, Plano D, Paredes J, Aldazabal J, Luquin M Biomacromolecules. 2022; 23(11):4629-4644.

PMID: 36288499 PMC: 9667499. DOI: 10.1021/acs.biomac.2c00853.


Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson's disease.

Wang Y, Wu S, Li Q, Lang W, Li W, Jiang X Front Pharmacol. 2022; 13:977521.

PMID: 36172194 PMC: 9511047. DOI: 10.3389/fphar.2022.977521.


Therapeutic Strategies for Immune Transformation in Parkinson's Disease.

Saleh M, Markovic M, Olson K, Gendelman H, Mosley R J Parkinsons Dis. 2022; 12(s1):S201-S222.

PMID: 35871362 PMC: 9535567. DOI: 10.3233/JPD-223278.


References
1.
Simola N, Morelli M, Frazzitta G, Frau L . Role of movement in long-term basal ganglia changes: implications for abnormal motor responses. Front Comput Neurosci. 2013; 7:142. PMC: 3805948. DOI: 10.3389/fncom.2013.00142. View

2.
Morris M, Martin C, Schenkman M . Striding out with Parkinson disease: evidence-based physical therapy for gait disorders. Phys Ther. 2009; 90(2):280-8. PMC: 2816030. DOI: 10.2522/ptj.20090091. View

3.
Frazzitta G, Balbi P, Maestri R, Bertotti G, Boveri N, Pezzoli G . The beneficial role of intensive exercise on Parkinson disease progression. Am J Phys Med Rehabil. 2013; 92(6):523-32. DOI: 10.1097/PHM.0b013e31828cd254. View

4.
Santini E, Valjent E, Fisone G . mTORC1 signaling in Parkinson's disease and L-DOPA-induced dyskinesia: A sensitized matter. Cell Cycle. 2010; 9(14):2713-8. DOI: 10.4161/cc.9.14.12323. View

5.
Petzinger G, Fisher B, Van Leeuwen J, Vukovic M, Akopian G, Meshul C . Enhancing neuroplasticity in the basal ganglia: the role of exercise in Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S141-5. PMC: 4111643. DOI: 10.1002/mds.22782. View